HWK-007

N/A

Report date: 2026/03/06 20:02:51

Base Information

Drug NameHWK-007
Drug Alias NameHWK-007
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsEndometrial NeoplasmsCarcinoma, Non-Small-Cell LungOvarian Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesWuxi Biologics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesWhitehawk Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsEndometrial NeoplasmsCarcinoma, Non-Small-Cell LungOvarian Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A